HC Wainwright & Co. Reiterates Buy on Outlook Therapeutics, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Outlook Therapeutics (NASDAQ:OTLK) and maintained a $30 price target.
May 17, 2024 | 2:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Outlook Therapeutics and maintained a $30 price target.
The reiteration of a Buy rating and a high price target of $30 by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100